Leone Patterson is Adverum’s president and chief executive officer and serves as a director. Ms. Patterson joined Adverum in June 2016 as chief financial officer and has served as chief executive officer since May 2018, director since October 2018, and president since December 2019. Ms. Patterson has 20 years of experience in the biotechnology industry. Previously, Ms. Patterson served as the chief financial officer of Diadexus, Inc. Earlier, Ms. Patterson was vice president and chief financial officer of Transcept Pharmaceuticals, Inc. until it was acquired by Paratek Pharmaceuticals Inc. Previously, Ms. Patterson served as vice president and global corporate controller of NetApp, Inc. In addition, Ms. Patterson was vice president of finance at Exelixis, Inc. Earlier in her career, Ms. Patterson worked at Novartis AG as vice president of global business planning and analysis after working at Chiron, which was acquired by Novartis AG. Ms. Patterson began her career at KPMG working in the firm’s audit practice. Ms. Patterson earned a B.S. in Business Administration and Accounting from Chapman University and an Executive M.B.A. from St. Mary’s College. Ms. Patterson is also a Certified Public Accountant (inactive status).
Adverum is a clinical-stage gene therapy company targeting unmet medical need in ocular and rare diseases. We develop gene therapy product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Our core capabilities include clinical development, novel vector discovery, and in-house manufacturing expertise, specifically in scalable process development, assay development, and current Good Manufacturing Practices (cGMP) quality control. Our team has extensive clinical development experience and is laser-focused on advancing novel gene therapies for patients.
At Adverum, our values underscore our business and shape how we think of the patients we hope to help, how we apply science to medicine, and how we work and grow as a company.